Innoviva reports Q2 EPS 77c vs. (55c) last year

Reports Q2 revenue $100.3M vs. $99.9M last year. “Innoviva (INVA) continued to deliver impressive financial and operational results last quarter, represented by strong performance from our GSK royalties portfolio, combined with significant momentum from our IST-marketed products. We successfully launched our fourth product, ZEVTERA, the first and only FDA-approved cephalosporin for MRSA-related Staphylococcus aureus bacteremia, in the U.S., and we are pleased with the market engagement,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “The FDA’s acceptance of the zoliflodacin NDA and granting of Priority Review mark critical regulatory milestones for this important product. We will be working diligently with the FDA toward the PDUFA target action date of December 15, 2025. If approved, single-dose oral zoliflodacin could be the first new antibiotic in decades for the treatment of gonorrhea. I believe recent advances attest to the success of our efforts to build a best-in-class business in the infectious disease and critical care space. We are also pleased with excellent progress across our strategic healthcare asset portfolio, including Armata Pharmaceuticals’ recently announced positive Phase 2 data in Staphylococcus aureus bacteremia.”